"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Descriptor ID |
D000970
|
MeSH Number(s) |
D27.505.954.248
|
Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 1 | 1 | 2 |
1998 | 4 | 0 | 4 |
1999 | 1 | 0 | 1 |
2000 | 1 | 0 | 1 |
2001 | 0 | 2 | 2 |
2002 | 1 | 1 | 2 |
2004 | 1 | 0 | 1 |
2005 | 1 | 1 | 2 |
2006 | 2 | 0 | 2 |
2007 | 1 | 0 | 1 |
2008 | 4 | 0 | 4 |
2009 | 1 | 1 | 2 |
2010 | 0 | 2 | 2 |
2011 | 1 | 0 | 1 |
2012 | 0 | 1 | 1 |
2013 | 1 | 1 | 2 |
2014 | 2 | 1 | 3 |
2015 | 3 | 1 | 4 |
2017 | 1 | 0 | 1 |
2018 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
2020 | 4 | 0 | 4 |
2022 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Phytochemicals in Inhibition of Prostate Cancer: Evidence from Molecular Mechanisms Studies. Biomolecules. 2022 09 16; 12(9).
-
Brain-derived neurotrophic factor overexpression in taste buds diminishes chemotherapy induced taste loss. Eur J Neurosci. 2022 10; 56(7):4967-4982.
-
Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA. Cell Death Dis. 2020 12 11; 11(12):1052.
-
Chemopreventive role of arabinoxylan rice bran, MGN-3/Biobran, on liver carcinogenesis in rats. Biomed Pharmacother. 2020 Jun; 126:110064.
-
Tranilast induces MiR-200c expression through blockade of RelA/p65 activity in leiomyoma smooth muscle cells. Fertil Steril. 2020 06; 113(6):1308-1318.
-
The role of PPM1D in cancer and advances in studies of its inhibitors. Biomed Pharmacother. 2020 May; 125:109956.
-
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer. Breast Cancer Res. 2019 02 21; 21(1):29.
-
Targeting of PP2Cd By a Small Molecule C23 Inhibits High Glucose-Induced Breast Cancer Progression In Vivo. Antioxid Redox Signal. 2019 06 10; 30(17):1983-1998.
-
Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int J Mol Sci. 2017 Nov 02; 18(11).
-
Five-year recurrence rate of lentigo maligna after treatment with imiquimod. Br J Dermatol. 2016 Jan; 174(1):165-8.